Health & Fitness
Mon, April 22, 2013Sun, April 21, 2013Fri, April 19, 2013Thu, April 18, 2013Wed, April 17, 2013Tue, April 16, 2013KaloBios' Targeted Antibacterial KB001-A to be Featured in BIO 2013 Panel Discussion of "New Defenses Against Old Enemies"
//health-fitness.news-articles.net/content/2013/ .. cussion-of-new-defenses-against-old-enemies.html
Published in Health and Fitness on Wednesday, April 17th 2013 at 20:00 GMT by Market Wire🞛 This publication is a summary or evaluation of another publication
KaloBios' Targeted Antibacterial KB001-A to be Featured in BIO 2013... -- SOUTH SAN FRANCISCO, Calif., April 17, 2013 /PRNewswire/ --
SOUTH SAN FRANCISCO, Calif., April 17, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals (Nasdaq: [ KBIO ]) today announced that David Pritchard , President and Chief Executive Officer, will speak at the BIO 2013 International Convention in Chicago, IL on Tuesday, April 23 as part of a panel entitled, "New Defenses Against Old Enemies: Vaccines and Biotherapies for Bacterial Infection."
(Logo: [ http://photos.prnewswire.com/prnh/20130225/MM66380LOGO ])
Mr. Pritchard will be discussing the company's targeted antibacterial agent against Pseudomonas aeruginosa (Pa), KB001-A. KaloBios is developing KB001-A for the management of Pa in the lungs of patients with cystic fibrosis, while the company's corporate partner Sanofi Pasteur is developing KB001-A for the prevention of ventilator-associated pneumonia caused by Pa.
Breakout Session: Innovations and Opportunities in Vaccines
Session ID 1877: New Defenses Against Old Enemies: Vaccines and Biotherapies for Bacterial Infection
When:Tuesday, April 23, 2013, 9:00 – 10:15 AM
Where: McCormick Place, Room S402A
About KaloBios
KaloBios Pharmaceuticals, Inc. is developing a portfolio of patient-targeted, first-in-class monoclonal antibodies to treat serious medical conditions with a primary clinical focus on respiratory diseases and cancer. For more information on KaloBios Pharmaceuticals, please visit our web site at [ http://www.kalobios.com ].
Contact:
Jeffrey H. Cooper
Chief Financial Officer
KaloBios Pharmaceuticals, Inc.
(650) 243-3146
[ ir@kalobios.com ]
Media Contact:
Joan E. Kureczka
Kureczka/Martin Associates
Tel: (415) 821-2413
Mobile: (415) 690-0210
[ Joan@Kureczka-Martin.com ]
SOURCE KaloBios Pharmaceuticals
RELATED LINKS
[ http://www.kalobios.com ]